MindBio Therapeutics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Net Income	-0.6	-0.41	-4.29	-7.47
Loss (Gain) From Sale of Investments	0.01	0.01	0.02	-
Stock-Based Compensation	-	-	1.4	-
Other Operating Activities	0.31	0.18	0.95	1.93
Change in Accounts Payable	0.25	-0.06	-0.4	0.87
Change in Unearned Revenue	-0.12	-0.12	0.12	-
Change in Other Net Operating Assets	-0	-0	-0.01	-0.04
Operating Cash Flow	-0.1	-0.38	-2.21	-4.72
Investment in Securities	-	-	-	-0.03
Investing Cash Flow	-	-	-	-0.03
Long-Term Debt Issued	-	-	-	6.38
Long-Term Debt Repaid	-	-0.01	-0.11	-
Net Debt Issued (Repaid)	-0.02	-0.01	-0.11	6.38
Issuance of Common Stock	0.17	-	1.15	-
Common Dividends Paid	-	-	-	-0.79
Other Financing Activities	-	0.28	-	-
Financing Cash Flow	0.14	0.27	1.04	5.59
Foreign Exchange Rate Adjustments	-0.07	-0.07	0.18	-
Net Cash Flow	-0.03	-0.18	-1	0.83
Levered Free Cash Flow	-0.47	-0.5	-1.39	-
Unlevered Free Cash Flow	-0.19	-0.28	-1.11	-
Change in Net Working Capital	-0.21	-0.12	0.5	-

Updated Jan 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.